1437 related articles for article (PubMed ID: 35473824)
1. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays.
Padoan A; Cosma C; Bonfante F; Rocca FD; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chim Acta; 2021 Dec; 523():446-453. PubMed ID: 34755646
[TBL] [Abstract][Full Text] [Related]
5. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
6. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
7. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
10. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
12. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
13. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
[TBL] [Abstract][Full Text] [Related]
16. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
19. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
[TBL] [Abstract][Full Text] [Related]
20. Two rapid SARS-CoV-2 disposable devices for semi-quantitative S-RBD antibody levels determination compared with CLIA and ELISA assays at different protective thresholds.
Padoan A; Cosma C; Galla L; Basso D; Plebani M
Clin Chim Acta; 2022 Apr; 529():104-108. PubMed ID: 35202620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]